Pipeline
Product
Disease
Preclinical
Phase I
Phase II
Phase III
Approved
Gastrointestinal
IBSRELA®
(tenapanor)
Irritable Bowel Syndrome with Constipation (IBS - C)
Approved
Nephrology
XPHOZAH®
(tenapanor)
Chronic Kidney Disease (CKD) with Hyperphosphatemia
Approved
Multiple Therapeutic Areas
RDX10531
Undisclosed
Preclinical
RDX10531
RDX10531 is a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas.
The safety and efficacy of the agents for the indications under investigation have not been established.
Commitment to Patients
We believe in working closely with patients and their caregivers, listening to their needs and insights, and setting new standards in product innovation, patient care, and community engagement.
Clinical Trials
We are grateful to all the individuals and families helping us advance our research through their participation in our clinical trials.
US-COR-0070v2